Skip to main content
MAZE logo

MAZE · Maze Therapeutics, Inc. · Executive Compensation

Track MAZE — free
$31.37 -1.06 (-3.27%) At close · Nov 20
Market Cap
$1.72B
Shares
54.68M
Volume · Nov 20 818.95K Avg daily vol (3M) 730.21K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Hervé Hoppenot Appointed 2026-08-17
Hervé Hoppenot Resigned 2026-08-17
Nancy C. Andrews, M.D., Ph.D. Appointed 2026-08-17
Nancy C. Andrews, M.D., Ph.D. Resigned 2026-08-17
Sophie Kornowski, Pharm.D. Appointed 2026-08-17
Paula A. Johnson, M.D., M.P.H. Appointed 2026-08-17
Amy Bachrodt
“Ms. Bachrodt’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices or on any matter relating to the Company’s financial reporting.”
Resigned 2026-05-22
Neil Kumar Appointed 2026-03-25
Hervé Hoppenot Appointed 2025-10-06
Hervé Hoppenot Appointed 2025-10-06
Misbah Tahir Appointed 2025-09-02

Leadership

Key facts CIK 1842295 CUSIP 578784100 13F (30d) 158 filings 153 filers Visit website Investor relations